<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39417610</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-7633</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Chembiochem : a European journal of chemical biology</Title><ISOAbbreviation>Chembiochem</ISOAbbreviation></Journal><ArticleTitle>Design and evaluation of peptide inhibitors targeting the dimerization of SARS-CoV-2 main protease.</ArticleTitle><Pagination><StartPage>e202400688</StartPage><MedlinePgn>e202400688</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cbic.202400688</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome virus 2 (SARS-CoV-2) seriously impacted public health. The evolutionarily conserved viral chymotrypsin-like main protease (Mpro) is an important target for anti-SARS-CoV-2 drug development. Previous studies have shown that the eight N-terminal amino acids (N8) of SARS-CoV Mpro are essential for its dimerization, and are used to design inhibitors against SARS-CoV Mpro dimerization. Here, we established a simple readout assay using SDS-PAGE and Coomassie blue staining to measure inhibitory activity of N8 peptide derived from SARS-CoV-2 Mpro. To optimize its inhibitory effect, we then modified the side-chain length, charge, and hydrophilicity of the N8 peptide, and introduced a mutated Mpro recognition sequence. As a result, we obtained a series of potent peptide inhibitors against SARS-CoV-2 Mpro, with N8-A24 being the most efficient with an IC50 value of 1.44 mM. We observed that N8-A24 reduced Mpro dimerization with an IC50 value of 0.86 mM. Molecular docking revealed that N8-A24 formed hydrogen bond interactions with critical dimeric interface residues, thus inhibiting its dimerization and activity. In conclusion, our study not only discovers a series of peptide inhibitors targeting the SARS-CoV-2 Mpro dimerization, but also provides a promising strategy for the rational design of new inhibitors against COVID-19.</AbstractText><CopyrightInformation>© 2024 Wiley‐VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Chongqing University, school of life sciences, Chongqing university Huxi campus, Shapingba, 401331, Chongqing, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chongqing University, School of Life Sciences, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhiyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Chongqing University, School of Life Sciences, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Chongqing University, School of Life Sciences, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chongqing University, School of Life Sciences, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shao-Lin</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Chongqing University, School of Pharmaceutical Sciences, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Aimin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chongqing University, school of life sciences, CHINA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Chembiochem</MedlineTA><NlmUniqueID>100937360</NlmUniqueID><ISSNLinking>1439-4227</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mpro</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">dimerization</Keyword><Keyword MajorTopicYN="N">peptide inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39417610</ArticleId><ArticleId IdType="doi">10.1002/cbic.202400688</ArticleId></ArticleIdList></PubmedData></PubmedArticle>